Exploratory post hoc analysis of a phase 3 trial in 746 DMARD-naive, ACPA-positive patients with early RA: high baseline IL-10 predicted better week-52 response to abatacept plus MTX vs placebo plus MTX, and 47 of 103 biomarkers fell more with abatacept.
Secondary analysisn = 746
Liu et al. Baseline Interleukin-10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease-Modifying Antirheumatic Drug Naive and Anti-Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis